Mesoporous High‐Entropy Oxides Nanoplatform Decodes Paired‐Plasma Metabolic Fingerprinting of Pancreatic Cancer
Advanced Materials · 2026-02 · 38 (9)
DOI: 10.1002/adma.202513988 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 05.12.2025. Verfasst von Yue Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Shanghai Stomatological Hospital & School of Stomatology, State Key Laboratory of Molecular Engineering of Polymers, Shangha…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Oxides, Metabolomics, Nanoparticles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, Fundamental Research Funds for the Central Universities, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Accurate detection of small molecule metabolites in vivo is critical for rapid screening of disease biomarkers and health monitoring. Matrix‐assisted laser desorption/ ionization mass spectrometry (MALDI‐MS) has emerged as a promising platform for metabolic profiling, but its capability is hindered by the limited light absorption and energy transfer of conventional matrix materials. In this work, a high‐efficiency metabolic detection platform based on high‐entropy oxide particles (mHEO) with an interconnected mesoporous structure and tailored compositions is established. Owing to their abundant active sites and excellent light utilization efficiency, the mHEO particles show significantly improved photothermal and photochemical properties with an eightfold localized enhanced electromagnetic field and higher surface temperatures (616 °C) than nonporous HEOs (336 °C). As a result, MALDI‐MS based on the mHEO matrix exhibits high sensitivity, good reproducibility (Coefficient of Variation < 10%), and ultralow detection limits with 1–3 orders of magnitude lower than their endogenous concentrations. Furthermore, the mHEO‐based MALDI‐MS platform is applied to analyze paired arterial/venous blood samples from pancreatic cancer (PC) patients with the assistance of machine learning. Four tumor microenvironment‐associated metabolites are identified as a potential biomarker panel of PC, achieving a robust pancreas‐venous plasma classification, which allows the timely screening and targeted treatment of PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Shanghai Stomatological Hospital & School of Stomatology, State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Fuda…
- School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, 315211, P. R. China.
- Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, P. R. China.
ORCID-Profile: Yonghui Deng
Förderung
- Science and Technology Commission of Shanghai Municipality
- Fundamental Research Funds for the Central Universities
- China Postdoctoral Science Foundation
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Zitieren
APA
Sun, Y., Xie, W., Shi, F., Li, J., Yu, H., Jiang, Y., Deng, C., & Deng, Y. (2026). Mesoporous High‐Entropy Oxides Nanoplatform Decodes Paired‐Plasma Metabolic Fingerprinting of Pancreatic Cancer. Advanced Materials, 38(9). https://doi.org/10.1002/adma.202513988
Vancouver
Sun Y, Xie W, Shi F, Li J, Yu H, Jiang Y, et al. Mesoporous High‐Entropy Oxides Nanoplatform Decodes Paired‐Plasma Metabolic Fingerprinting of Pancreatic Cancer. Advanced Materials. 2026;38(9). doi:10.1002/adma.202513988
BibTeX
@article{Sun2026,
author = {Sun, Yue and Xie, Wenhe and Shi, Fangying and Li, Jichun and Yu, Hongxiu and Jiang, Yongjian and Deng, Chunhui and Deng, Yonghui},
title = {Mesoporous High‐Entropy Oxides Nanoplatform Decodes Paired‐Plasma Metabolic Fingerprinting of Pancreatic Cancer},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {9},
doi = {10.1002/adma.202513988}
}
EUVIMED